1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Fishman Retires from Novartis; New Research Head Appointed

 
• By Lucie Ellis-Taitt

Novartis AG has named Dr. James E. Bradner president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the company's executive committee – effective March 1, 2016. Bradner will replace Dr. Mark C. Fishman, who is retiring after 13-years leading Novartis's discovery and early clinical development efforts.

Novartis AG has named Dr. James E. Bradner president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the company's executive committee – effective March 1, 2016. Bradner will replace Dr. Mark C. Fishman, who is retiring after 13-years leading Novartis's discovery and early clinical development efforts.

"Mark has done an outstanding job leading NIBR, and he will be missed," said CEO Joe Jimenez. He added that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Therapy Areas

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.